Latest Breaking News On - ஃப்ரெட் ர்ஸ் - Page 2 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results March 17, 2021 GMT DARTMOUTH, Nova Scotia (BUSINESS WIRE) Mar 17, 2021 IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and year ended December 31, 2020. “Notwithstanding the challenges everyone faced in 2020, IMV’s commitment to provide effective and well-tolerated immunotherapies to patients with hard-to-treat cancer resulted in significant progress on multiple fronts with our lead compound, Maveropepimut-S, and with other DPX-based candidates,” said Fred Ors, Chief Executive Officer at IMV Inc. “We see 2021 as a transformational year for IMV as we are advancing Maveropepimut-S in both relapsed, refractory DLBC

United statesBristol meyers squibbAndrew hallNeil berinsteinRelationsmarc jasminAmerican society of hematology annual meetingSociety for immunotherapy of cancerSunnybrook health sciences centerClinical program updatesFred orsChief executive officerRel studyAmerican societyHematology annualAnniversary annual meetingProgression free survival